Søren Bregenholt
Directeur Général chez ALLIGATOR BIOSCIENCE AB
Fortune : 74 485 $ au 30/04/2024
Postes actifs de Søren Bregenholt
Sociétés | Poste | Début | Fin |
---|---|---|---|
ALLIGATOR BIOSCIENCE AB | Directeur Général | 01/06/2021 | - |
Public Communications Contact | - | - | |
Medicon Valley Alliance FMBA
Medicon Valley Alliance FMBA Miscellaneous Commercial ServicesCommercial Services Medicon Valley Alliance FMBA operates a life science cluster that spans across Denmark and Sweden. The non-profit company is based in the Medicon Valley region. | Président | - | - |
A Bioscience Incentive AB | Président | - | - |
Atlas Therapeutics AB
Atlas Therapeutics AB Pharmaceuticals: MajorHealth Technology Part of Alligator Bioscience AB, Atlas Therapeutics AB develops and manufactures antibody drugs. The company is based in Stockholm, Sweden. Atlas Therapeutics was acquired by Alligator Bioscience AB on October 18, 2013. | Président | - | - |
Oblique Therapeutics AB
Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Søren Bregenholt
Anciens postes connus de Søren Bregenholt
Sociétés | Poste | Début | Fin |
---|---|---|---|
NOVO NORDISK A/S | Directeur en chef des Investissements | 09/06/2010 | - |
Corporate Officer/Principal | - | 09/06/2010 | |
Macrophage Pharma Ltd.
Macrophage Pharma Ltd. BiotechnologyHealth Technology Macrophage Pharma Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Berkhamsted, the United Kingdom. | Directeur/Membre du Conseil | 03/09/2019 | - |
Directeur Général | 03/09/2019 | - | |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Directeur des opérations | 24/04/2009 | - |
Corporate Officer/Principal | 01/01/2002 | 11/09/2009 |
Formation de Søren Bregenholt
University of Copenhagen | Doctorate Degree |
Statistiques
Internationale
Danemark | 5 |
Suède | 5 |
Royaume-Uni | 2 |
Opérationnelle
Chairman | 3 |
Corporate Officer/Principal | 2 |
Director/Board Member | 2 |
Sectorielle
Health Technology | 7 |
Consumer Services | 2 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
NOVO NORDISK A/S | Health Technology |
ALLIGATOR BIOSCIENCE AB | Health Technology |
Entreprise privées | 6 |
---|---|
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Health Technology |
Macrophage Pharma Ltd.
Macrophage Pharma Ltd. BiotechnologyHealth Technology Macrophage Pharma Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Berkhamsted, the United Kingdom. | Health Technology |
Medicon Valley Alliance FMBA
Medicon Valley Alliance FMBA Miscellaneous Commercial ServicesCommercial Services Medicon Valley Alliance FMBA operates a life science cluster that spans across Denmark and Sweden. The non-profit company is based in the Medicon Valley region. | Commercial Services |
A Bioscience Incentive AB | |
Atlas Therapeutics AB
Atlas Therapeutics AB Pharmaceuticals: MajorHealth Technology Part of Alligator Bioscience AB, Atlas Therapeutics AB develops and manufactures antibody drugs. The company is based in Stockholm, Sweden. Atlas Therapeutics was acquired by Alligator Bioscience AB on October 18, 2013. | Health Technology |
Oblique Therapeutics AB
Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | Health Technology |
- Bourse
- Insiders
- Søren Bregenholt
- Expérience